If you’ve already registered, please click here to log in to the webcast.

In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART-19) products for relapsed/refractory B cell lymphomas and leukemia. However, only ~30-40% of patients maintain a durable complete remission at long term.

In this webcast, Dr. Marco Ruella, an internationally recognized expert in cellular immunotherapies, will present research to improve CAR-T therapy for cancer by studying tumor evasion mechanisms and other limitations of CAR-T immunotherapy, and to rationally design novel approaches to overcome them.

Several interrelated factors contribute to the lack of response or relapse after CART-19, including tumor cell-intrinsic factors, CAR-T cell dysfunction, and an immunosuppressive tumor microenvironment (TME). This presentation will describe uses of a combination of next-generation techniques (scRNA sequencing, spatial transcriptomics, etc.) to characterize mechanisms of resistance, perform pre-clinical studies, and develop new CAR-T products.

• Mechanisms of resistance to CAR-T cells
• Next-generation techniques to study and develop novel CAR-T products
• Caveats on improving manual perturbation issues, highlighting rare sample management and the value of fit-for-purpose screening